Why Cytek Biosciences, Inc.’s (CTKB) Stock Is Up 6.07%
As of Thursday, June 25, Cytek Biosciences, Inc.’s CTKB share price has surged by 6.07%, which has investors questioning if this is right time to sell.Michael Rose
| SECTOR | INDUSTRY |
| Health Care | Life Sciences Tools & Services |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Michael Rose
Michael Rose
Rosalio Madrigal
Cynthia McLaughlin
Jenna Brashear
| Share Statistics | CTKB | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $556.6 | $1,774.7 | 39% |
|
| Shares Out (Mil) | 128.7 | 94.8 | 68% |
|
| Institutional Ownership | 83.7% | 90.1% | 52% |
|
| Float (Mil) | 96.6 | 69.9 | 61% |
|
| Beta | 1.17 | 1.20 | 69% |
|
| Avg Daily Volume (000s) | 648 | 838 | 63% |
|
| Price Change (52-week) |
19.7% | 81.0% | 62% |
|
| Growth | CTKB | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 16.8% | 7.8% | 77% |
|
| Net Income (5yr) | (40.3%) | (13.7%) | 9% |
|
| EPS (5yr) | (48.5%) | 0.7% | 4 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.0%) | (15.0%) | 52% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.020) | ($0.030) | $0.200 | |
| Month Ago EPS | ($0.010) | ($0.040) | $0.190 | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.050) | ($0.130) | $0.060 | |
| Year/Year Chg | (86.7%) | (94.2%) | (155.7%) | |
| Financials | CTKB | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $204 | $763 | 32% |
|
| Net Income (TTM) (Mil) | ($74) | ($14) | 13% |
|
| EPS (TTM) | ($0.579) | ($0.200) | 26% |
|
| Operating Cash Flow (TTM) (Mil) | ($7) | $53 | 22% |
|
| Net Cash Flow (TTM) (Mil) | ($30) | ($5) | 23% |
|
| Long-Term Debt (Q1) (Mil) | $14 | $270 | 30% |
|
| Enterprise Value (Q1) (Mil) | $354 | $2,430 | 31% |
|
| Valuation | CTKB | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.70 | 3.00 | 45% |
|
| P/E | na | 43.5 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 5.3 | na |
|
| Ratios | CTKB | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 51.7% | 47.6% | 64% |
|
| Net Margin | (36.2%) | (2.9%) | 14% |
|
| ROA | (15.9%) | (3.2%) | 22% |
|
| ROE | (20.9%) | (4.5%) | 23% |
|
| Liabilities to Assets | 27.0% | 43.0% | 18% |
|
| F-Score | 2 | 5 | 7% |
|
Passing Stock Screens
As of 7/30/2026, from a list of 60 stock screening strategies,
| Performance Since Inception: | 13.1% |
| +/- S&P 500: | +5.6 |
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors